Physician profile
Wen Chen
NPI 1346447620
$1,552.17
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $232 · 2021: $63.92 · 2022: $90.19 · 2023: $32.71 · 2024: $721 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $250.00 | 2024-2025 | Vemlidy |
| Genentech USA, INC. | $230.40 | 2019-2022 | |
| Eisai INC. | $207.34 | 2024 | |
| Abbott Laboratories | $138.37 | 2024 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $130.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| Livanova USA, INC. | $82.93 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $40.06 | 2019-2020 | |
| Pfizer INC. | $32.71 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $24.54 | 2021 | |
| Emd Serono, INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.